Mesirow Financial Investment Management Inc. Sells 880 Shares of Halozyme Therapeutics, Inc. $HALO

Mesirow Financial Investment Management Inc. lowered its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,566 shares of the biopharmaceutical company’s stock after selling 880 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Halozyme Therapeutics were worth $498,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new stake in Halozyme Therapeutics in the first quarter valued at approximately $32,000. SVB Wealth LLC bought a new position in Halozyme Therapeutics during the 1st quarter worth $33,000. Bessemer Group Inc. increased its position in Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 207 shares during the period. Brooklyn Investment Group increased its holdings in shares of Halozyme Therapeutics by 1,558.1% during the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 670 shares during the period. Finally, CWM LLC increased its position in shares of Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 438 shares during the period. 97.79% of the stock is owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $69.03, for a total value of $1,380,600.00. Following the sale, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $50,648,622.57. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $75.24, for a total transaction of $150,480.00. Following the completion of the sale, the director directly owned 44,952 shares in the company, valued at $3,382,188.48. This trade represents a 4.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 108,227 shares of company stock worth $7,779,595 in the last ninety days. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $65.19 on Friday. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. The stock’s fifty day simple moving average is $71.16 and its two-hundred day simple moving average is $62.53. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $79.50. The stock has a market cap of $7.63 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 0.35 and a beta of 1.16.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company had revenue of $325.72 million for the quarter, compared to analyst estimates of $282.66 million. During the same period last year, the firm earned $0.91 earnings per share. The firm’s revenue was up 40.8% on a year-over-year basis. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research note on Monday, October 27th. Leerink Partners upgraded Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price target on the stock in a report on Tuesday, October 14th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, October 21st. Morgan Stanley reduced their target price on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating on the stock in a report on Monday, October 20th. Finally, The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a research report on Thursday, July 10th. They set a “neutral” rating and a $55.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $73.11.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.